Policy is the main subject here. Its use is separating a proposed budget cut from an enacted change, then linking bills and CMS consultation to real effects on research funding, treatment access, benefit timing, documentation, and billing.

Keep this for evidence triage rather than bedside answers. The value is the reminder that a conference preview can flag high-impact neurology studies, but full trial methods and results still need review before any change reaches routine care.

Brief but practical for anyone who reads practice-changing papers. Letters and author replies show where the real disagreement sits, clarify what a study was trying to say, and stop publication being treated as the end of scrutiny.

The reason not to reassure yourself with existing migraine options is the unmet need this short update names. It explains why TRPM8 blockade is being tested when acute therapies work inadequately or inconsistently, while keeping the line clear between biological promise and proven benefit.

The pressure point is operational strain that starts to touch patient care. This short listen is useful for anyone leading a service, because it separates funding, staffing, administration and care delivery pressures and turns a vague sense of overload into something a team can act on.

The clue is rising seizure frequency or a request for dose review during pregnancy, especially with lamotrigine. Open this for a practical schedule: regular antenatal increases, a taper starting about two days after delivery, and a postpartum target still slightly above baseline.

Do not treat a new approval headline as a complete account of the evidence. This short critical appraisal episode clarifies what a one-trial FDA default means, what it does not mean, and why that distinction matters when new therapies or devices are discussed.

The action here is not to ask whether AI exists, but how it is constrained. This episode is useful because it shows a safer model: institution-only protocols, source-cited answers, after-hours demand, and clinical questions that centre on seizure care, dosing, and brain death workflows.

The pitfall is calling failed treatment or missed review simple non-adherence. This is worth hearing for a practical framework that links housing, education, disability, and structural factors to whether neurological medication plans and follow-up can realistically succeed.

The reason not to reassure yourself is that a technically sound neurology plan can still fail when medication cost or food insecurity blocks access. This listen is worth opening for one practical change: ask directly about social barriers when seizures worsen or follow-up stops making sense.